Analyst Reco. Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Market Closed - Nasdaq Other stock markets 21:00:00 30/04/2024 BST			5-day change	1st Jan Change
17.94 ^USD	+5.22%		+14.63%	+63.99%

04-23	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	MT
04-22	RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	04-22	MT
Piper Sandler Starts Edgewise Therapeutics With Overweight Rating, $48 Price Target	03-07	MT
Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating	02-23	MT
Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating	11-10	MT
JPMorgan Adjusts Price Target on Edgewise Therapeutics to $25 From $24, Maintains Overweight Rating	30/06/23	MT
JPMorgan Adjusts Price Target on Edgewise Therapeutics to $24 From $25, Maintains Overweight Rating	16/05/23	MT
Truist Securities Starts Edgewise Therapeutics at Buy With $25 Price Target	01/05/23	MT
Wedbush Trims Edgewise Therapeutics' Price Target to $27 From $28 After Minor Adjustments to Estimates, Keeps Outperform Rating	24/02/23	MT
RBC Cuts Price Target on Edgewise Therapeutics to $29 From $31, Maintains Outperform, Speculative Risk Rating	04/11/22	MT
Wedbush Adjusts Edgewise Therapeutics Price Target to $28 From $31, Maintains Outperform Rating	03/11/22	MT
Goldman Sachs Downgrades Edgewise Therapeutics to Sell From Neutral, Keeps $5 Price Target	25/08/22	MT
Goldman Sachs Adjusts Edgewise Therapeutics' Price Target to $5 from $8, Keeps Neutral Rating	24/05/22	MT
JPMorgan Adjusts Price Target for Edgewise Therapeutics to $28 From $32, Maintains Overweight Rating	24/05/22	MT
Goldman Sachs Adjusts Price Target for Edgewise Therapeutics to $8 From $11, Maintains Neutral Rating	12/05/22	MT
SVB Securities Adjusts Edgewise Therapeutics' Price Target to $30 from $34, Keeps Outperform Rating	12/05/22	MT
RBC Initiates Edgewise Therapeutics at Outperform, Speculative Risk With $31 Price Target, Bullish on '5506 Treatment for Muscular Dystrophies	13/04/22	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $32 from $33, Maintains Overweight Rating	14/02/22	MT
Goldman Sachs Starts Edgewise Therapeutics at Neutral With $11 Price Target	28/01/22	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $33 from $30, Keeps Overweight Rating	06/01/22	MT
JPMorgan Adjusts Edgewise Therapeutics' Price Target to $30 From $35, Reiterates Overweight Rating	02/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Analyst Reco.

Filters